Logo

CytRx Expands RNAi Collaboration with U Mass Med School

Apr 30, 2003

NEW YORK, April 30 - CytRx of Los Angeles said today that it has expanded its collaboration with University of Massachusetts Medical School, signing an sponsored-research agreement as the first phases of a drug-development effort in obesity and type II diabetes.

 

Michael Czech, chairman of the molecular medicine, will head the research effort that will apply RNAi-directed gene silencing to fat cells for target validation.

 

In early April, CytRx announced that it had signed a license agreement with UMMS for its proprietary portfolio of applications for RNAi-based gene silencing technology in obesity, type 2 diabetes, and cancer.

 

Interested in more on RNAi? Read GenomeWeb's weekly roundup of activity.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.